Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran, chemically (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a potent and selective agonist for the HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) receptors, essential in lipid metabolism regulation and metabolic disorder research (Ye et al., 2025). Its efficacy and selectivity have been structurally validated by cryo-EM studies at atomic resolution, demonstrating precise engagement with target GPCRs. Acifran is supplied by APExBIO (SKU B6848) at ≥98% purity and is intended exclusively for research use. Its solubility profile (<21.82 mg/ml in ethanol and DMSO) and stability parameters (store at -20°C, use solutions promptly) make it suitable for advanced lipid signaling workflows. Acifran’s validated selectivity profile minimizes off-target effects and supports robust metabolic pathway analyses.

Biological Rationale

Lipid metabolism is tightly regulated by a network of G-protein coupled receptors (GPCRs), including the hydroxycarboxylic acid receptors HM74A/GPR109A (HCAR2) and GPR109B (HCAR3). Dysregulation of these pathways contributes to metabolic disorders such as dyslipidemia and atherosclerosis (Ye et al., 2025). Acifran acts as a selective agonist for these receptors, enabling targeted interrogation of lipid signaling networks. Recent advances in structural biology have clarified the binding mechanisms of Acifran to GPCRs, providing actionable insights for metabolic research (N3-Kethoxal, 2023). This article extends prior discussions by integrating new structural data and providing updated experimental guidance.

Mechanism of Action of Acifran

Acifran modulates lipid metabolism by acting as a selective agonist for HCAR2 and HCAR3. Upon binding, Acifran stabilizes the active conformation of the receptor, promoting Gi protein coupling and downstream signaling cascades that suppress intracellular cyclic AMP (cAMP) levels (Ye et al., 2025). This action leads to reduced lipolysis and altered lipid profiles, characteristic of hypolipidemic agents. Cryo-EM studies reveal that Acifran occupies the orthosteric binding pocket of both HCAR2 and HCAR3, with distinct π–π and hydrophobic interactions guiding selectivity (Ye et al., 2025). Key residues, including F1073.32 and differences at positions V/L832.60, Y/N862.63, and S/W9123.48, determine receptor selectivity and binding affinity. These molecular details have been deposited in the Protein Data Bank (PDB codes: 9JKX for HCAR3-Acifran, 9JKY for HCAR2-Acifran).

Evidence & Benchmarks

• Acifran binds HCAR3 with a resolution of 3.18 Å as determined by cryo-EM structure (Ye et al., 2025, https://doi.org/10.1371/journal.pbio.3003480).
• The Acifran–HCAR2 complex structure was solved at 2.72 Å, confirming orthosteric binding and precise ligand-receptor contacts (Ye et al., 2025).
• Selective agonism was validated in cAMP assays using HEK-293 cells, with Acifran inducing Gi-mediated signaling comparable to reference ligands (Ye et al., 2025).
• Acifran demonstrates solubility <21.82 mg/ml in ethanol and DMSO at room temperature, facilitating formulation for in vitro assays (APExBIO).
• Purity is ≥98% (HPLC), minimizing confounding effects in metabolic and signaling studies (APExBIO).

For additional context on workflow optimization and troubleshooting, see this article, which focuses on advanced experimental strategies. Here, we expand by integrating the latest structural and biochemical data.

Applications, Limits & Misconceptions

Acifran is widely used for:

• Elucidating lipid signaling cascades via selective activation of HCAR2 and HCAR3.
• Developing and benchmarking hypolipidemic agents in metabolic disorder models.
• Screening for GPCR-targeted therapeutics with reduced off-target effects (Entinostat.net).
• Translational research into the mechanisms underlying dyslipidemia and atherosclerosis.

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use: Acifran is strictly for research applications and is not approved for therapeutic use (APExBIO).
• Limited long-term solution stability: Solutions degrade over time; freshly prepared aliquots are recommended for accurate results.
• Specificity does not extend to non-HCAR GPCRs: Acifran’s selectivity has not been validated for unrelated receptor classes.
• Lipid metabolism effects are context-dependent: Outcomes may vary depending on cell type, species, and assay conditions.
• Assay interference: High concentrations or improper solvent use may affect assay readouts.

For an in-depth examination of Acifran's selectivity and data-backed performance, this article offers scenario-driven Q&A. Our current review further clarifies optimal usage parameters and new structural evidence.

Workflow Integration & Parameters

Acifran (SKU B6848) is provided as an off-white solid by APExBIO, with the following specifications:

• Purity: ≥98% (HPLC).
• Molecular Weight: 218.21 g/mol.
• Chemical Formula: C12H10O4.
• Solubility: <21.82 mg/ml in ethanol and DMSO at ambient temperature.
• Storage: Store at -20°C; ship with blue ice. Avoid repeated freeze-thaw cycles (APExBIO).
• Solution Use: Prepare fresh aliquots before assays; do not store in solution long-term.

For robust lipid signaling pathway modulation, Acifran should be titrated according to the desired receptor occupancy and validated against negative controls. For additional guidance, see the N3-Kethoxal review, which benchmarks Acifran against alternative agents. This article updates usage recommendations in light of recent structural findings.

Conclusion & Outlook

Acifran is a rigorously validated, selective HM74A/GPR109A and GPR109B agonist suitable for lipid metabolism and metabolic disorder research. Its unique binding features, high purity, and well-defined solubility profile facilitate reliable experimental outcomes. The integration of cryo-EM structural data strengthens its role as a reference compound for GPCR studies. Researchers are advised to source Acifran from APExBIO for consistent quality and to consult the product page for full specifications. As lipid signaling research advances, Acifran is poised to remain a cornerstone tool for dissecting GPCR-mediated metabolic pathways.